Asset Details
Do you wish to reserve the book?
Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment
Do you wish to request the book?
Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment
1997
Overview
Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin
treatment.
G Tonolo ,
M Ciccarese ,
P Brizzi ,
L Puddu ,
G Secchi ,
P Calvia ,
M M Atzeni ,
M G Melis and
M Maioli
Servizio Diabetologia, University of Sassari, Italy.
Abstract
OBJECTIVE: To study the long-term effects of simvastatin on urinary albumin excretion rate (AER) in normotensive microalbuminuric
type 2 diabetic patients with hypercholesterolemia. RESEARCH DESIGN AND METHODS: A total of 19 normotensive microalbuminuric
hypercholesterolemic type 2 diabetic patients entered a double-blind crossover study for 2 years, receiving either simvastatin
(20 mg/day) or placebo (each treatment for 1 year). RESULTS: Simvastatin significantly decreased plasma cholesterol (total
and LDL) after 52 weeks of treatment. A concomitant significant decrease of AER (25% from basal) with no significant changes
in creatinine clearance was observed during the same period. CONCLUSIONS: Our data are in keeping with the hypothesis that
simvastatin might be used as an additional means to preserve renal function in microalbuminuric hypercholesterolemic type
2 diabetic patients.
Publisher
American Diabetes Association
Subject
/ Aged
/ Anticholesteremic Agents - therapeutic use
/ Associated diseases and complications
/ Biological and medical sciences
/ Diabetes
/ Diabetes Mellitus, Type 2 - complications
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetes Mellitus, Type 2 - physiopathology
/ Diabetes. Impaired glucose tolerance
/ Diabetic Nephropathies - etiology
/ Diabetic Nephropathies - metabolism
/ Diabetic Nephropathies - urine
/ Endocrine pancreas. Apud cells (diseases)
/ Female
/ Humans
/ Hypercholesterolemia - complications
/ Hypercholesterolemia - drug therapy
/ Hypercholesterolemia - metabolism
/ Lipids
/ Male
/ Patients
/ Plasma
